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Abstract. Non-steroidal nuclear receptors play a major role in 
breast cancer development. A correlation among, and possible 
prognostic function of, the members of the nuclear receptor 
superfamily has been discussed controversially over the 
years. Hence, we conducted a quantification of the different 
expression levels of the thyroid receptor (TR), retinoid X 
receptor (RXR), peroxisome proliferator-activated receptor 
(PPAR) and vitamin D receptor (VDR) in malignant breast 
tumour tissue samples. Patients diagnosed and treated for 
breast cancer between 1990 and 2000 were included. Receptor 
expression was detected by immunohistochemical staining. 
Correlation analyses for the expression of the receptors were 
performed for the clinical and histopathological data. The 
paraffin‑embedded tissue from 82 breast cancer patients was 
available. The different steroid receptors showed varying 
results when correlated with known histopathological markers. 
TRα2 demonstrated the most significant correlations with 
steroid hormone receptors. Significant correlations between 
the major isoforms of TR, and between RXR, PPAR and VDR, 
were demonstrated in the patient sample. The immunohisto-
chemical association of these receptors may provide the first 
proof of an interaction on the molecular level. This assumption 
awaits confirmation in studies with larger cohorts.
Introduction
Although the involvement of the oestrogen receptor (ER) and 
progesterone receptor (PR) in breast cancer development and 
growth is well-established, little is known about the relevance 
and correlation of steroid hormone receptors with other 
members of the related non-steroidal nuclear receptor family. 
The latter is divided into two subfamilies (1), the first including 
the oestrogen, androgen, progesterone and mineralocorticoid 
receptors and the second including the thyroid receptor (TR), 
vitamin D receptor (VDR), retinoic acid receptor (RAR), 
peroxisome proliferator-activated receptor (PPAR) and reti-
noid X receptor (RXR). The second group of receptors is 
able to form heterodimers with each other, function through 
appropriate ligands (2) and interact at the genetic level (3).
The immunohistochemical expression of these recep-
tors in breast cancer cells is known (4) and their expression 
levels are higher than in normal breast tissue or benign breast 
lesions (5‑8). 
The hormone dependency of the mammary gland and the 
similarity of TR and ER/PR have led to the hypothesis that 
TR may be a prognostic marker in breast cancer patients (9). 
The ER has two isoforms (α and β), which are differentiated 
by their molecular construction yet identical in their basic 
effect (10). In this study, which focuses on ER detected at the 
time of first diagnosis of breast cancer, ER isoform α expres-
sion was measured since this is the main isoform for which 
the most authentic histopathological data have been shown in 
previous studies (11). PR was also detected at the time of the 
first breast cancer diagnosis.
In the case of the TRs, immunohistochemical staining 
of the best known isoforms was conducted. The three main 
isoforms are TRα1, TRα2 and TRβ1 (12), which show high 
homology in amino acid composition. 
Synthetic ligands of RXR have been reported to induce 
arrest of growth and differentiation in breast cancer cells 
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in vitro and in animal models (13,14). Ligand activation of 
RXR and PPAR induces antitumour effects in breast cancer 
cells (15). For RXR, three isoforms exist (α, β and γ). The 
best data on their detection in malignant breast tumours are 
available for RXRα (8). For PPAR, most studies refer to the γ 
isoform (13,16). 
VDR is expressed in epithelial, stromal and immune cells 
of the normal mammary gland and is dynamically regulated 
in the epithelial compartment during hormonal changes (17). 
Furthermore, the receptor exists in malignant dividing cell 
types which respond to 1,25 vitamin D3 (18).
The present study is an evaluation of the potential corre-
lations among different steroid hormone receptors following 
their immunohistochemical detection.
Materials and methods
Patients and ethics. Patients with an initial diagnosis of 
anamnestic sporadic breast cancer who received treatment 
in the Department of Obstetrics and Gynaecology of the 
Ludwig-Maximilians-University (Munich, Germany) and 
whose tissue samples were obtained at the surgery in our insti-
tution between 1990 and 2000 were included. Patients were 
stratified into groups according to lymph node involvement, 
grading and histopathological type, as described previ-
ously (19). 
Ethical approval was obtained from the local ethics 
committee at the University of Munich (Project No. 048‑08). 
The participants provided written informed consent. The 
study was carried out according to the guidelines of the 
1975 Declaration of Helsinki. All samples and clinical infor-
mation were used anonymously.
TNM classification was conducted according to the WHO 
criteria (20). The histological grading classification proposed by 
Bloom and Richardson was determined according to a modi-
fication of the Elston and Ellis grading system (21). Further 
clinical and histopathological parameters collected included 
age, year of breast cancer diagnosis, tumour size, histopatho-
logical type, axillary node involvement, histological grading 
and oestrogen/progesterone receptor status. At the time of the 
tissue extraction, Her-2/neu was not regularly investigated in 
Germany. As far as possible, it has now been determined for the 
existing slides. Values of 0 and 1 were considered to be negative, 
values of 3+ were classified as positive and in cases of 2+, a 
fluorescence in situ hybridisation (FISH) assay was performed. 
Histological diagnostic evaluation and staging were 
performed by two experienced gynecologic pathologists.
Clinical data on the patients' diseases were available from 
patients' charts, aftercare files and tumour registry database 
information.
Immunohistochemistry. Immunohistochemistry was 
performed using a combination of pressure cooker heating and 
the standard streptavidin-biotin-peroxidase complex with the 
use of the mouse/rabbit-IgG-Vectastain Elite ABC kit (Vector 
Laboratories, Burlingame, CA, USA). The antibodies used for 
staining are listed in Table I. 
Briefly, paraffin-fixed tissue sections were dewaxed 
with xylol for 15 min and then rehydrated in descending 
concentrations of alcohol (100, 75 and 50%). Endogenous 
peroxidase activity was quenched by dipping the slides 
into 3% hydrogen peroxide (Merck, Darmstadt, Germany) 
in methanol for 20 min. For epitope retrieval, the sections 
were then incubated in a pressure cooker using sodium 
citrate buffer (pH 6.0) containing 0.1 M citric acid and 0.1 M 
sodium citrate in distilled water for 10 min. After cooling, 
the slides were washed in phosphate-buffered saline (PBS) 
twice. Non‑specific binding of the primary antibodies was 
blocked by incubating the sections with diluted normal 
serum (10 ml PBS containing 150 µl horse/goat serum and 
50 µl secondary antibody; Vector Laboratories) for 20 min at 
room temperature. Sections were incubated in diluted bioti-
nylated secondary antibody (10 ml PBS containing 150 µl 
horse/goat serum and some secondary antibody; Vector 
Laboratories) for 30 min and the avidin-biotin peroxidase 
complex (diluted in 10 ml PBS; Vector Laboratories) for 
30 min. Visualisation was performed using the substrate 
and the chromogen 3,3'‑diaminobenzidine (DAB; Dako, 
Glostrup, Denmark). Sections were counterstained with 
Mayer's acidic haematoxylin, dehydrated in an ascending 
Table I. Antibodies and working concentrations.
Antibody Species isotype Working dilution Source
TRα1/2 Polyclonal rabbit IgG 1:200  Abcam, Cambridge, MA, USA
TRα1 Polyclonal rabbit IgG   1:1000  AbD Serotec Oxford, UK
TRα2 Monoclonal rabbit IgG1 1:200  AbD Serotec, Oxford, UK
TRβ1/2 Polyclonal rabbit IgG  1:200  Zytomed, Berlin, Germany
TRβ1 Polyclonal rabbit IgG 1:200  Millipore, Schwalbach, Germany
TRβ2 Polyclonal rabbit IgG 1:100  Millipore, Schwalbach, Germany
RXRα Mouse monoclonal IgG 1:150 Perseus Proteomics Inc., Tokyo, Japan
PPARγ Rabbit polyclonal IgG   1:1000 Abcam, Cambridge, MA, USA
VDR Mouse monoclonal IgG2a 1:100 AbD Serotec, Oxford, UK
TR, thyroid receptor; RXR, retinoid X receptor; PPAR, peroxisome proliferator‑activated receptor; VDR, vitamin D receptor.
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series of alcohol concentrations and then covered. The deter-
mination of the different receptors is shown in Fig. 1A-D. 
Negative and positive controls (placental tissue) were used to 
assess the specificity of the immunoreactions. For negative 
controls (coloured blue), isotype-matched control antibodies 
of the same species (Dako, Hamburg, Germany) were 
applied to the breast cancer tissue. The control tissue showed 
neither nuclear nor cytoplasmic staining. Negative controls 
and unstained cells were blue (Fig. 1E). Positive cells were 
brown (Fig. 1F).
Slides were evaluated and digitalised with a Zeiss photo-
microscope (Axiophot; AxioCam, Zeiss, Jena, Germany). 
The immunoreactive score (IRS) was assigned according to 
Remmele and Stegner (22). The intensity and distribution 
patterns of specific immunohistochemical staining were 
evaluated using the semi-quantitative assay (23,24). The IRS 
score was calculated by multiplying the optical staining inten-
sity (graded as 0, no staining; 1, weak staining; 2, moderate 
staining; 3, strong staining) with the percentage of posi-
tively stained cells (0, no staining; 1, <10% of cells stained; 
2, 11‑50% of cells stained; 3, 51‑80% of cells stained; 4, >81% 
of cells stained). Microscopic analysis was performed by two 
independent observers.
Statistical analysis. Statistical analysis was performed using 
SPSS version 19.0 (PASW Statistics; SPSS Inc., IBM, Chicago, 
IL, USA). Correlation analysis of the receptor expression was 
performed using the non-parametric Mann-Whitney U test and 
the non-parametric Spearman's rho. All statistical tests were 
two‑sided and P<0.05 was considered to indicate a statistically 
significant result.
Results
Patient characteristics. The paraffin-embedded tissues of 
82 patients were available for analyses. The age at primary 
diagnosis ranged from 54-95 years. All patients had received 
an initial diagnosis of breast cancer and had an invasive ductal 
histopathological type. Patient characteristics are detailed in 
Table II.
The detection of TR, RXR and PPAR expression was 
limited to the nuclei. However, VDR expression was also 
found in the cytoplasm of the tumours (Fig. 1A-D). Positive 
immunohistochemical results (Table III) and correlations with 
known histopathological markers were identified (Table IV).
The results of the single TRα1/2 antibodies with a median 
IRS of 4 (range, 0-12) differed from the combined antibody 
TRα1/2. For TRα1/2, the IRS median was 0 (range, 0-6).
Table II. Baseline characteristics of participants.
Factor n %
Tumour size 82 100
  pT1a   1     1
  pT1b 15   18
  pT1c 44   54
  pT2 17   21
  pT3 -   -
  pT4   5     6
LNI 82 100
  Yes 38   46
  No 44   54
Grading 82 100
  1   9   11
  2 40   49
  3 33   40
TR 82 100
  α1/2 78   95
  α1 78   95
  α2 79   96
  β1/2 77   94
  β1 79   96
  β2 76   93
RXRα 78   95
PPARγ 78   95
VDR 75   91
LNI, lymph node involvement; TR, thyroid receptor; RXR, retinoid 
X receptor; PPAR, peroxisome proliferator‑activated receptor; VDR, 
vitamin D receptor.
Figure 1. Immunohistochemical staining of (A) TR, (B) RXR, (C) PPAR and 
(D) VDR in human breast cancer tissue. The images show immunoreactions 
following incubation of tumour cells with the primary antibody (x10 and 
x25 lens). (E and F) Placental tissue serves as negative and positive controls 
for the receptors (here RXR). (E) For negative controls (blue), the isotypes 
matching the control antibodies of the same species were used. (F) Positive 
control shows TR staining of villous trophoblast cells. TR, thyroid receptor; 
RXR, retinoid X receptor; PPAR, peroxisome proliferator‑activated receptor; 
VDR, vitamin D receptor.
  A   B
  C   D
  E   F
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As for TRα1/2, the median IRS values of the individual 
TRβ1 and TRβ2 antibodies were higher with values of 2 and 
3, respectively (range, 0-12). The TRβ1/2 results were compa-
rable to those for TRα1/2 with a median IRS of 1 (range, 0-9).
For RXR, the median IRS value was 4 (range, 0‑8) and for 
PPAR it was 2 (range, 0-12). VDR showed the highest value 
with an IRS of 8 (range, 0‑12).
Correlation analysis among the histopathological param‑
eters. Tumour size, lymph node involvement and grading were 
significantly correlated with each other (data not shown). ER/
PR had no significant associations with tumour size, lymph 
node involvement or grading.
Correlation analysis of steroid family members with histo‑
pathological findings
Tumour size. Tumour size was negatively correlated with 
TRα1 [correlation coefficient (cc)=‑0.357, P=0.001], TRα2 
(cc=‑0.329, P=0.003), TRβ1 and TRβ2 expression (cc=‑0.293, 
P=0.009; cc=‑0.314, P=0.006). TRα2 levels were higher in 
pT1 tumours (median IRS, 6) compared with pT2-4 tumours 
(P=0.024; Fig. 2). RXR and PPAR were not associated with 
tumour size. In correlation analyses, VDR was negatively 
associated with tumour size (cc=‑0.278, P=0.016).
Axillary lymph node involvement. Lymph node involve-
ment was negatively correlated with TRα2 (cc=‑0.487, 
P=0.002) and VDR (cc=‑0.411, P<0.01). However, only PPARγ 
had a positive significant correlation with lymph node involve-
ment (cc=0.318, P=0.005).
Differentiation grading. Differentiation grading was 
negatively correlated with TRα2 (cc=‑0.542, P=0.009) and 
RXRγ (cc=‑0.248, P=0.029). Positive correlations of grading 
were only observed with PPARγ (cc=0.236, P=0.038).
Furthermore, the correlation analysis of ER/PR expression 
(data shown in Table IV) showed positive results for TRα2 
expression in the tumours (cc=0.248, P=0.028) and also for 
TRβ1 (cc=0.252, P=0.025). A negative correlation was found 
between TRβ1/2 expression and ER/PR expression (cc=‑0.349, 
P=0.002). For RXR, PPAR and VDR, the correlation analysis 
showed no significant values for ER/PR expression.
Her‑2/neu. As determined by retrospective analyses, 
most patients had a negative Her‑2 status (60/82, 80%). In 
7 patients it was not possible to determine Her-2 expression. 
No significant correlations were demonstrated with other 
clinicopathological parameters (Table IV).
Correlations among the members of the steroid hormone 
receptor family. The results of the correlations among the 
single functionally related steroid hormone receptors are 
listed in detail in Table V.
Thyroid receptors. For the combined TRα1/2, a correlation 
was demonstrated with TRα1, TRβ1, TRβ2 and RXR. TRα1 
expression was correlated with TRα1/2, TRβ2 and RXR. 
TRα2 showed positive correlations with TRβ2, RXR and 
VDR. No correlations with other steroid factors were found 
for TRβ1/2. TRβ1 correlated positively with TRβ2, PPAR 
and VDR. TRβ2 showed positive correlations with almost all 
receptors (TRα1/2, TRα1, TRα2, TRβ1, PPAR and VDR).
RXR. RXRα was positively correlated with TRα1, TRα2 
and TRα1/2.
PPAR. PPARγ showed two correlations, with TRβ1 and 
TRβ2.
VDR. For VDR, significant correlations were demon-
strated with TRα2, TRβ1 and TRβ2.
Discussion
The present study demonstrated significant correlations 
between the known histopathological parameters, including 
tumour size, lymph node involvement, differentiation grade, 
ER, PR and other members of the nuclear receptor family. 
Furthermore, significant correlations among different steroid 
receptors (excluding the combined TRβ1/2) were shown. To 
the best of our knowledge, this is the first study to examine the 
coexpression and thus the immunohistochemical correlation 
between members of steroid receptors in a cohort of breast 
cancer patients.
Figure 2. Box plot analysis of TRα2 and tumour size. The box plots show a 
higher IRS of TRα2 in small malignant breast tumours. IRS, immunoreactive 
score; TR, thyroid receptor.
Table III. Immunohistochemical staining results of all receptors.
 IRS negative (0-1) IRS positive (2-12)
Antigen n (%) n (%)
TR
  α1 23 (29) 55 (71)
  α2 25 (32) 54 (78)
  α1/2 59 (76) 19 (24)
  β1 36 (46) 43 (54)
  β2 16 (21) 60 (79)
  β1/2 44 (57) 33 (43)
RXRα 11 (14) 74 (86)
PPARγ 33 (42) 45 (58)
VDR 6 (8) 89 (92)
IRS, immunoreactive score; TR, thyroid receptor; RXR, retinoid X 
receptor; PPAR, peroxisome proliferator‑activated receptor; VDR, 
vitamin D receptor.
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The rationale for this study was the known significance 
of immunohistochemical ER/PR expression in breast cancer 
and the similarity of these receptors with the surface of the 
other members of the nuclear receptor family. In the latter, 
ER/PR detection in breast cancer is associated with prognostic 
relevance (25), and it has long been known that overexpression 
is treatable with antihormonal therapy (26), regardless of the 
oestrogen and progesterone blood levels.
Certain authors have focused on thyroid receptors due 
to an assumed correlation between thyroid dysfunction 
and breast cancer (9,27,28). Few studies have reported 
clear results demonstrating associations, although in these 
studies, TRs and other histopathological findings were not 
further differentiated; for example, a negative correlation 
between the TR receptor level and the axillary involvement 
of lymph nodes (29). By contrast, Silva et al did not find 
clear correlations between single TRβ1 expression and other 
histopathological factors (30). The inconsistency between 
the results of different TRs may be attributable to different 
distributions of the TRs in the examined tissue (certain 
Table IV. Correlations of antibodies with histopathological data.
Antigen Tumour size (pT) LNI Differentiation grade ER/PR Her-2/neu
TRα1/2 ns ns ns ns ns
TRα1 cc=‑0.357, P=0.001 ns ns ns ns
TRα2 cc=‑0.329, P=0.003 cc=‑0.487, P=0.002 cc=‑0.542, P=0.009 cc=0.248, P=0.028 ns
TRβ1/2 ns ns ns cc=‑0.349, P=0.002 ns
TRβ1 cc=‑0.293, P=0.009 ns ns cc=0.252, P=0.025  ns
TRβ2 cc=‑0.314, P=0.006 ns ns ns ns
RXRα ns ns cc=‑0.248, P=0.029 ns ns
PPARγ ns cc=0.318, P=0.005 cc=0.225, P=0.047 ns ns
VDR cc=‑0.278, P=0.016 cc=0.411, P<0.01 ns ns ns
LNI, lymph node involvement; ER, oestrogen receptor; PR, progesterone receptor; TR, thyroid receptor; RXR, retinoid X receptor; 
PPAR, peroxisome proliferator‑activated receptor; VDR, vitamin D receptor; cc, coefficient of correlation; ns, not statistically significant. 
Data presented as correlation coefficient and P‑values.
Table V. Correlations among TR, RXR, PPAR and VDR antibodies.
Antigen TRα1/2 TRα1 TRα2 TRβ1/2 TRβ1 TRβ2 RXRα PPARγ VDR
TRα1/2 ‑ cc=0.300 ns ns cc=0.247 cc=0.287 cc=0.274 ns ns 
  P=0.009   P=0.032 P=0.014 P=0.018
TRα1 cc=0.300 ‑ ns ns ns cc=0.291 cc=0.399 ns ns 
 P=0.009     P=0.013 P=0.000
TRα2 ns ns ‑ ns ns cc=0.282 cc=0.316 ns cc=0.433
      P=0.014 P=0.006  P=0.000
TRβ1/2 ns ns ns - ns ns ns ns ns
TRβ1 cc=0.247 ns ns ns ‑ cc=0.557 ns cc=0.270 cc=0.403
 P=0.032     P=0.000  P=0.017  P=0.000
TRβ2 cc=0.287 cc=0.291 cc=0.282 ns cc=0.557 ‑ ns cc=0.458 cc=0.370
 P=0.014 P=0.013 P=0.014  P=0.000   P=0.000 P=0.001
RXRα cc=0.274 cc=0.399 cc=0.316 ns ns ns ‑ ns ns
 P=0.018 P=0.000 P=0.006
PPARγ ns ns ns ns cc=0.270 cc=0.458 ns ‑ ns
     P=0.017 P=0.000
VDR ns ns cc=0.433 ns cc=0.403 cc=0.370 ns ns ‑
   P=0.000  P=0.000 P=0.001
TR, thyroid receptor; RXR, retinoid X receptor; PPAR, peroxisome proliferator‑activated receptor; VDR, vitamin D receptor; cc, coefficient of 
correlation; ns, not statistically significant. Data presented as correlation coefficient and P‑values.
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sections had mainly mixed epitopes of TRs, while other 
sections had mainly single TRs). Taking this into account, 
as was demonstrated in our study, clear associations between 
different TRs and histopathological findings support the 
assumption that the interactions identified may have inherent 
prognostic relevance.
As with TRs, most of the literature for RXR and PPAR does 
not refer to in vivo but in vitro data (31,32). In our study, the 
expression of RXR, which is known for its antitumour effects, 
was negatively correlated with differentiation grade (33).
For PPARγ, an inverse association with tumour size was 
found (34). In contrast to our previous findings (35), which 
demonstrated a correlation between PPAR and positive 
lymph node involvement, discrepant results have also been 
reported (34). These current conflicting results need to be 
resolved in larger trials. Hence, drawing clinical conclusions 
from these findings is considered premature at this time.
In a previous study (36), an immunohistochemical 
expression of VDR in most of the tumour cells was shown. 
Nonetheless, data based on the correlation between VDR 
and ER/PR were inconsistent and contradictory (36-39). 
Furthermore, the presence of ER/PR and VDR was only 
partially correlated with other clinical features of tumour 
stage (36). 
We cannot underline the finding of a clear association of 
VDR and ER/PR but, in contrast to previous findings, our data 
demonstrated a correlation between VDR, tumour size and 
lymph node involvement. A single study (40) demonstrated a 
role for vitamin D and its receptor in breast cancer in humans. 
As previous data have shown (41,42), an improved outcome 
was achieved in patients with high VDR-IRS than in patients 
with low IRS. Taken together, the current findings support the 
assumption that VDR is a factor with prognostic relevance in 
breast cancer.
The immunohistochemical association of these recep-
tors supports the knowledge of interactions at the molecular 
level (43). Hence, these results await confirmation in larger 
trials. Unfortunately, HER2/neu status was not routinely 
determined in the cohort investigated at the time of initial 
diagnosis. Given the high prognostic value of HER2/neu 
status, it was of significant interest whether this prognosti-
cator also interacts with other receptors. Although selection 
bias cannot be excluded and the number of patients was small, 
results may have significance for malignant breast tumour 
diseases and may be of interest for future innovative thera-
peutic approaches.
We have demonstrated significant correlations for all 
the major isoforms of TRs, and furthermore, between RXR, 
PPAR and VDR. Significantly, and in contrast to TRβ2, TRα2 
demonstrated significant correlations with each of the known 
independent histopathological markers in breast cancer. It was 
unusual that, with larger tumour size, higher differentiation 
grade and axillary lymph node involvement, TRα2 became 
negative, but with high ER/PR values, TR increased. This may 
lead to the assumption that high expression, particularly of 
TRα2, is associated with a better prognosis at higher values 
of ER/PR and therefore protects breast cancer cells from 
de-differentiation. Furthermore, TRβ2, RXR and VDR were 
significantly correlated, the latter two of which are known to 
be of prognostic importance in breast cancer.
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